New User:

-or-
Username:
Password:
Forgot your password?

Stock Market & Financial Investment News

News Breaks
March 31, 2014
11:38 EDTCYTK, GALT, ATHNOptions with increasing implied volatility: CYTK GALT ATHN
News For CYTK;GALT;ATHN From The Last 14 Days
Sign up for a free trial to see the rest of the stories you've been missing.
October 20, 2014
07:37 EDTCYTKCytokinetics completes review results from BENEFIT-ALS regarding tirasemtiv
Cytokinetics provided a program update today relating to tirasemtiv, the company's lead drug candidate from its skeletal muscle contractility program. The company announced that it has completed its review of results from BENEFIT-ALS and has concluded that effects observed on Slow Vital Capacity in patients treated with tirasemtiv are robust and potentially clinically meaningful. In addition, following consultation with clinical and statistical experts, the company believes that data from BENEFIT-ALS support progression of tirasemtiv to a potential Phase III clinical trial in patients with amyotrophic lateral sclerosis (ALS). The company also announced that it has begun regulatory interactions with the U.S. Food and Drug Administration regarding results from BENEFIT-ALS and has received initial feedback from the FDA. The company believes that effects on SVC could be a Phase III clinical trial endpoint and could support registration of tirasemtiv as a potential treatment for patients with ALS. As a result, Cytokinetics has initiated planning for a potential Phase III clinical trial of tirasemtiv that could begin in 2015. Cytokinetics has received feedback from the FDA following initial communications regarding tirasemtiv and BENEFIT-ALS. The company believes that the FDA may be willing to consider a potential registration path for tirasemtiv relating to effects on SVC. The company expects to have additional interactions with the FDA and other regulatory authorities. In addition, the company has commenced Phase III readiness activities including designing a potential Phase III clinical trial in order to inform plans, timelines and costs associated with the further development of tirasemtiv.
06:38 EDTATHNathenahealth price target lowered to $115 from $140 at RBC Capital
Subscribe for More Information
October 17, 2014
09:17 EDTATHNOn The Fly: Pre-market Movers
Subscribe for More Information
08:05 EDTATHNathenahealth reports Q3 adjusted EPS 27c, consensus 27c
athenahealth last night reported Q3 revenue $190.4M, consensus $190.4M. The company reported it grew net new active physicians on athenaCollector, which had 3,420 physicians added, athenaClinicals, which had 2,786 physicians added, and athenaCommunicator, which had 3,846 physicians added, for the three months ended September 30.
October 16, 2014
18:36 EDTATHNOn The Fly: After Hours Movers
Subscribe for More Information
16:07 EDTATHNathenahealth now sees FY14 EPS near high end of range
athenahealth said, "We are not making any changes to the fiscal year 2014 guidance...However, based on our year-to-date performance and current expectations for Q4 2014, we are providing additional insight into our fiscal year 2014 guidance as follows: "We expect GAAP Total Revenue to be at or above the mid-point of the $725M-$755M guidance range. We expect Non-GAAP Adjusted Gross Margin to be close to the mid-point of the 62.5% to 63.5% guidance range. We expect Non-GAAP Adjusted Net Income per Diluted share to be close to the high end of the 98c-$1.10 guidance range."
16:05 EDTATHNathenahealth sees FY14 adjusted EPS 98c-$1.10, consensus $1.09
Subscribe for More Information
October 13, 2014
07:35 EDTCYTKCytokinetics announces development program update for CK-2127107
Subscribe for More Information

Sign up for a free trial to see the rest of the stories you've been missing.

I agree to the theflyonthewall.com disclaimer & terms of use